UroGen Pharma

(NASDAQ) URGN

Current Price$40.12

Market Cap$1.96B

Since IPO (2017)+188%

5 Year+161%

1 Year+161%

1 Month+23%

UroGen Pharma last closing stock price
Metric	Price	Date
Last close	USD 40.23	2026-07-17

UroGen Pharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+4.33%	USD 38.56	2026-07-10
1 month	+22.62%	USD 32.81	2026-06-17
3 month	+78.48%	USD 22.54	2026-04-17
Year to date	+71.78%	USD 23.42	2025-12-31
1 year	+161.06%	USD 15.41	2025-07-17
3 year	+330.27%	USD 9.35	2023-07-18
5 year	+161.06%	USD 15.41	2021-07-16
Since inception	+187.77%	USD 13.98	2017-05-04

UroGen Pharma Financials at a Glance

Market Cap

$1.96B

Revenue (TTM)

$140.49M

Net Income (TTM)

-$133.23M

EPS (TTM)

-$2.76

P/E Ratio

-14.60

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Price

$40.12

Volume

61,055

Open

$39.66

Price

$40.12

Volume

61,055

Open

$39.66

Previous Close

$40.12

Daily Range

$39.66 - $41.72

52-Week Range

$15.04 - $41.88

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Price

$40.12

Volume

61,055

Open

$39.66

Previous Close

$40.12

Daily Range

$39.66 - $41.72

52-Week Range

$15.04 - $41.88

Estimated Earnings Date

Aug 6, 2026

URGN News

UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

Jonathan PoncianoJul 12, 2026

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?

Cory RenauerJun 30, 2026

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

Cory RenauerJun 14, 2026

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

Jonathan PoncianoMay 23, 2026

Page 1

URGN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About UroGen Pharma

UroGen makes gel medicines to treat bladder and kidney cancers. These products help patients avoid surgery by treating tumors directly. The company focuses on specific urinary tract diseases for adults.

Gels, Tubes, and Tumors

Jelmyto: Gel-based treatment for low-grade cancer in the upper urinary tract; prolongs tissue exposure to medication.
Zusduri: Medicine applied to the bladder to treat recurrent low-grade tumors without requiring surgical removal.
RTGel Technology: Proprietary liquid that turns into a gel at body temperature to prevent medicine from washing away.
Pipeline Candidates: Investigational drugs like UGN-103 and UGN-501 targeting aggressive or recurrent bladder cancer types.

Strategic Shifts and Deals

Partnered with medac in January 2024 to create new medicine formulations with improved production costs.
Bought assets from IconOVir in February 2025 to acquire a new virus-based therapy for cancer.
Finished enrolling patients for the Phase 3 UTOPIA trial in July 2025 to test a next-generation bladder treatment.
Stopped the development of UGN-301 in November 2025 to focus on higher priority research projects.

The Power of RTGel

UroGen stands out by turning liquid drugs into long-lasting gels that stay in the body for hours. This method allows higher drug doses to reach hard-to-access areas like the upper urinary tract.

The Financial Scorecard

Revenue reached $37.8 million in Q4 2025, up 54% from $24.6 million in Q4 2024.
Gross profit hit $34.5 million in Q4 2025, up 56.4% year-over-year.
Net income reached -$26.4 million in Q4 2025, improving from a loss of $37.5 million in Q4 2024.
Operating cash flow was -$38.3 million in Q4 2025, worsening from -$13.6 million in Q4 2024.

Evolution and Outlook

UroGen has evolved into a commercial biotech company focused on non-surgical treatments for specialty urologic cancers. Its core technology changes how doctors deliver medicine to patients with chronic urinary diseases.

AI Generated • May 1, 2026

Industry

Biotechnology

Sector

Health Care

Employees

291

CEO

Elizabeth Barrett, MBA

Website

www.urogen.com

Headquarters

Princeton, NJ 08540, US

URGN Financials

Key Financial Metrics (TTM)

Gross Margin

89.85%

Operating Margin

-77.02%

Net Income Margin

-94.83%

Return on Equity

121.52%

Return on Capital

-546.26%

Return on Assets

-52.51%

Earnings Yield

-6.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.96B

Shares Outstanding

48.72M

Volume

61.05K

Avg. Volume

825.76K

Financials (TTM)

Gross Profit

$126.24M

Operating Income

-$108.21M

EBITDA

-$115.78M

Operating Cash Flow

-$165.74M

Capital Expenditure

-$299.00K

Free Cash Flow

-$166.04M

Cash & ST Invst.

$141.60M

Total Debt

$197.09M

UroGen Pharma Performance Analysis

UroGen Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 64,357,000	34.0%
2023	2023-12-31	USD 82,713,000	28.5%
2024	2024-12-31	USD 90,398,000	9.3%
2025	2025-12-31	USD 109,788,000	21.4%

UroGen Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	19.6%
Q3	2025-09-30	13.5%
Q4	2025-12-31	37.7%
Q1	2026-03-31	34.7%

UroGen Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -4.81	-2.9%
2023	2023-12-31	USD -3.55	-26.3%
2024	2024-12-31	USD -2.96	-16.6%
2025	2025-12-31	USD -3.19	7.8%

UroGen Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-14.1%
Q3	2025-09-30	34.3%
Q4	2025-12-31	21.7%
Q1	2026-03-31	13.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$50.96M

+151.6%

Gross Profit

$46.82M

+161.2%

Gross Margin

91.88%

N/A

Market Cap

$1.96B

N/A

Market Cap/Employee

$6.74M

N/A

Employees

291

N/A

Net Income

-$23.57M

+46.2%

EBITDA

-$19.00M

+51.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$141.60M

-27.7%

Total Debt

$197.09M

+57.7%

Accounts Receivable

$55.41M

+182.2%

Inventory

$20.92M

+175.6%

Long Term Debt

$195.18M

+56.2%

Short Term Debt

$1.92M

N/A

Return on Assets

-52.51%

N/A

Return on Invested Capital

-53.29%

N/A

Free Cash Flow

-$45.37M

-7.8%

Operating Cash Flow

-$45.32M

-7.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NRIXNurix Therapeutics, Inc.

NRIXNurix Therapeutics, Inc.$23.12+0.22%

KODKodiak Sciences Inc.

KODKodiak Sciences Inc.$42.64+3.37%

ANABAnaptysBio, Inc.

ANABAnaptysBio, Inc.$58.00+7.11%

XNCRXencor, Inc.

XNCRXencor, Inc.$17.47+16.86%

PHATPhathom Pharmaceuticals, Inc.

PHATPhathom Pharmaceuticals, Inc.$10.94-0.27%

OCSOculis Holding AG

OCSOculis Holding AG$12.19-3.33%

BBOTBridgeBio Oncology Therapeutics Inc.

BBOTBridgeBio Oncology Therapeutics Inc.$8.56+3.01%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$6.53-0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98-0.04%

INTCIntel

INTCIntel$95.04-0.02%

NOKNokia

NOKNokia$10.12-0.03%

PATHUiPath

PATHUiPath$12.15+0.01%

JOBYJoby Aviation

JOBYJoby Aviation$7.23-0.01%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$123.99-0.05%

Questions About URGN

What is the current price of UroGen Pharma?

UroGen Pharma is trading at $40.12 per share.

What is the 52-week range for UroGen Pharma?

Over the past 52 weeks, UroGen Pharma has traded between $15.04 and $41.88.

How much debt does UroGen Pharma have?

As of the most recent reporting period, UroGen Pharma reported total debt of $197.09M.

How much cash does UroGen Pharma have on hand?

UroGen Pharma reported $111.30M in cash and cash equivalents in its most recent financial results.

What is UroGen Pharma’s dividend yield?

UroGen Pharma does not currently have a dividend yield.

UroGen Pharma

UroGen Pharma Financials at a Glance

URGN News

UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally

UroGen (URGN) Q2 Revenue Rises 11%

Why Shares of UroGen Pharma Jumped Friday

Are These 3 Beaten-Down Biotech Stocks Bargains Now?

URGN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About UroGen Pharma

Gels, Tubes, and Tumors

Strategic Shifts and Deals

The Power of RTGel

The Financial Scorecard

Evolution and Outlook

URGN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

UroGen Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About URGN

What is the current price of UroGen Pharma?

What is the 52-week range for UroGen Pharma?

How much debt does UroGen Pharma have?

How much cash does UroGen Pharma have on hand?

What is UroGen Pharma’s dividend yield?

Premium Investing Services